CLAIMS:

1. A composition of matter comprising an extract of a plurality of peanuts, wherein said peanuts are at a R5 developmental stage , wherein said extract comprises heat-denatured allergenic proteins of said peanuts, wherein said composition of matter is essentially devoid of fully mature peanuts.

2. The composition of claim 1, being hypoallergenic in a subject that is allergic to the native form of said allergenic proteins.

3. A food product comprising the composition of matter of claims 1 or 2.

4. An article of manufacture comprising an aliquot of the composition of matter of claims 1 or 2, which comprises 1-10 g of peanut protein.

5. A method of generating a composition of matter comprising an extract of peanuts, the method comprising:

(a) selecting peanuts at an R5 developmental stage; (b) isolating the peanuts according to step (a) so as to generate a collection of peanuts which are devoid of mature peanuts, (c) heating said collection of peanuts for a length of time that denatures at least one allergenic protein of said peanuts, thereby generating the composition.

6. The method of claim 5, wherein said heating is carried out at a temperature between 50-500 ºC for at least 1 hour.

7. The method of claim 5, wherein said selecting is effected using x-ray technology.

8. The method of claim 5, further comprising generating a powder from said peanuts prior to said processing.

9. A composition of matter generated according to the method of any one of claims 6-8.

10. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for reducing allergenicity of peanuts in an allergic subject, wherein said denatured proteins are derived from peanuts at a R5 developmental stage, wherein said extract is essentially devoid of fully mature peanuts.

11. The use of claim 10, wherein said peanut extract is formulated for oral administration.

12. The use of claim 10, wherein said extract is provided in an amount between 0.1 - 2 gr of protein per week.

13. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for preventing allergenicity of peanuts in a subject, wherein said denatured proteins are derived from peanuts at a R5 developmental stage, wherein said extract is essentially devoid of fully mature peanuts.

14. The use of claim 13, wherein said subject is an infant.